MEP26408A - Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics - Google Patents

Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

Info

Publication number: MEP26408A
Authority: ME; Montenegro
Prior art keywords: group; compounds; hydrogen atom; cycloalkyl; general formula
Prior art date: 2004-01-16

Application number

MEP-264/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Ahmed Abouabdellah

Garcia Antonio Almario

Jacques Froissant

Christian Hoornaert

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-16

Filing date

2005-01-07

Publication date

2010-06-10

2005-01-07 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-06-10 Publication of MEP26408A publication Critical patent/MEP26408A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Virology (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)

MEP-264/08A 2004-01-16 2005-01-07 Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics MEP26408A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0400389A FR2865205B1 (fr)	2004-01-16	2004-01-16	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
PCT/FR2005/000028 WO2005077898A1 (fr)	2004-01-16	2005-01-07	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
MEP26408A true MEP26408A (en)	2010-06-10

Family

ID=34707893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-264/08A MEP26408A (en)	2004-01-16	2005-01-07	Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics

Country Status (28)

Country	Link
US (3)	US7439257B2 (no)
EP (1)	EP1708994B1 (no)
JP (1)	JP4705590B2 (no)
KR (1)	KR101171462B1 (no)
CN (1)	CN100537534C (no)
AR (1)	AR047384A1 (no)
AT (1)	ATE369336T1 (no)
AU (1)	AU2005212868B2 (no)
BR (1)	BRPI0506918A (no)
CA (1)	CA2552565C (no)
CY (1)	CY1106918T1 (no)
DE (1)	DE602005001930T2 (no)
DK (1)	DK1708994T3 (no)
ES (1)	ES2289701T3 (no)
FR (1)	FR2865205B1 (no)
HR (1)	HRP20070421T3 (no)
IL (1)	IL176769A (no)
MA (1)	MA28343A1 (no)
ME (1)	MEP26408A (no)
NO (1)	NO20063681L (no)
NZ (1)	NZ548530A (no)
PL (1)	PL1708994T3 (no)
PT (1)	PT1708994E (no)
RS (1)	RS50518B (no)
RU (1)	RU2392269C2 (no)
TW (1)	TWI402067B (no)
WO (1)	WO2005077898A1 (no)
ZA (1)	ZA200605698B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2865205B1 (fr) *	2004-01-16	2006-02-24	Sanofi Synthelabo	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) *	2004-02-26	2007-08-31	Sanofi Synthelabo	Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) *	2004-02-26	2006-05-05	Sanofi Synthelabo	Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) *	2004-04-20	2007-09-11	Rambus Inc.	Memory controller for non-homogenous memory system
EP2607362B1 (en)	2005-02-17	2014-12-31	Astellas Pharma Inc.	Piperidine and piperazine carboxylates as FAAH inhibitors
US8197472B2 (en)	2005-03-25	2012-06-12	Maquet Cardiovascular, Llc	Tissue welding and cutting apparatus and method
US7918848B2 (en)	2005-03-25	2011-04-05	Maquet Cardiovascular, Llc	Tissue welding and cutting apparatus and method
US7541359B2 (en)	2005-06-30	2009-06-02	Janssen Pharmaceutica N.V.	N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
WO2008023720A1 (en) *	2006-08-23	2008-02-28	Astellas Pharma Inc.	Urea compound or salt thereof
PT2089417E (pt)	2006-10-12	2015-04-14	Bhi Ltd Partnership	Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
EP2094683B1 (en) *	2006-12-06	2011-10-12	GlaxoSmithKline LLC	Bicyclic compounds and use as antidiabetics
CL2008002384A1 (es) *	2007-08-15	2009-07-17	Glaxo Group Ltd	Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
JP2011500634A (ja) *	2007-10-16	2011-01-06	グラクソグループリミテッド	炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
US9968396B2 (en)	2008-05-27	2018-05-15	Maquet Cardiovascular Llc	Surgical instrument and method
US9402679B2 (en)	2008-05-27	2016-08-02	Maquet Cardiovascular Llc	Surgical instrument and method
US9402680B2 (en)	2008-05-27	2016-08-02	Maquet Cardiovasular, Llc	Surgical instrument and method
TW201044234A (en) *	2009-06-08	2010-12-16	Chunghwa Picture Tubes Ltd	Method of scanning touch panel
US9955858B2 (en) *	2009-08-21	2018-05-01	Maquet Cardiovascular Llc	Surgical instrument and method for use
RU2012135525A (ru) *	2010-01-20	2014-02-27	Санофи	Производные алкилгетероциклических карбаматов, их получение и применение в терапии

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH605793A5 (fr) *	1974-03-05	1978-10-13	Soc Et Scient Et Ind	Procédé de préparation de nouveaux N-(1benzylpyrrollidinil 2-alkyl) benzamides substitués
CA2308850C (en) *	1997-11-24	2007-07-10	The Scripps Research Institute	Inhibitors of gap junction communication
JP4949552B2 (ja)	1998-04-16	2012-06-13	エンサイシブ・フアーマシユーテイカルズ，インコーポレイテツド	インテグリンのそれの受容体への結合を阻害するｎ，ｎ−ジ置換アミド
FR2816938B1 (fr) *	2000-11-22	2003-01-03	Sanofi Synthelabo	Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002087569A1 (en) *	2001-04-27	2002-11-07	Bristol-Myers Squibb Company	Bisarylimidazolyl fatty acid amide hydrolase inhibitors
EP1472215A4 (en) *	2002-02-08	2007-05-09	Bristol Myers Squibb Co	(OXIME) CARBAMOYL, FATTY ACID AMIDE HYDROLASE INHIBITORS
FR2843964B1 (fr) *	2002-08-29	2004-10-01	Sanofi Synthelabo	Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
CN100408556C (zh) *	2002-10-07	2008-08-06	加利福尼亚大学董事会	通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
US7662971B2 (en) *	2002-10-08	2010-02-16	The Scripps Research Institute	Inhibitors of fatty acid amide hydrolase
FR2850377B1 (fr)	2003-01-23	2009-02-20	Sanofi Synthelabo	Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) *	2004-01-16	2006-02-24	Sanofi Synthelabo	Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

2004
- 2004-01-16 FR FR0400389A patent/FR2865205B1/fr not_active Expired - Fee Related
2005
- 2005-01-07 AU AU2005212868A patent/AU2005212868B2/en not_active Ceased
- 2005-01-07 ME MEP-264/08A patent/MEP26408A/xx unknown
- 2005-01-07 ZA ZA200605698A patent/ZA200605698B/en unknown
- 2005-01-07 CA CA2552565A patent/CA2552565C/fr not_active Expired - Fee Related
- 2005-01-07 HR HR20070421T patent/HRP20070421T3/xx unknown
- 2005-01-07 BR BRPI0506918-1A patent/BRPI0506918A/pt active Search and Examination
- 2005-01-07 WO PCT/FR2005/000028 patent/WO2005077898A1/fr not_active Ceased
- 2005-01-07 ES ES05717376T patent/ES2289701T3/es not_active Expired - Lifetime
- 2005-01-07 DK DK05717376T patent/DK1708994T3/da active
- 2005-01-07 NZ NZ548530A patent/NZ548530A/en not_active IP Right Cessation
- 2005-01-07 JP JP2006548339A patent/JP4705590B2/ja not_active Expired - Fee Related
- 2005-01-07 PT PT05717376T patent/PT1708994E/pt unknown
- 2005-01-07 DE DE602005001930T patent/DE602005001930T2/de not_active Expired - Lifetime
- 2005-01-07 CN CNB2005800050936A patent/CN100537534C/zh not_active Expired - Fee Related
- 2005-01-07 KR KR1020067016045A patent/KR101171462B1/ko not_active Expired - Fee Related
- 2005-01-07 PL PL05717376T patent/PL1708994T3/pl unknown
- 2005-01-07 EP EP05717376A patent/EP1708994B1/fr not_active Expired - Lifetime
- 2005-01-07 RU RU2006129640/04A patent/RU2392269C2/ru not_active IP Right Cessation
- 2005-01-07 RS RSP-2007/0371A patent/RS50518B/sr unknown
- 2005-01-07 AT AT05717376T patent/ATE369336T1/de active
- 2005-01-11 TW TW094100762A patent/TWI402067B/zh not_active IP Right Cessation
- 2005-01-13 AR ARP050100111A patent/AR047384A1/es active IP Right Grant
2006
- 2006-07-10 IL IL176769A patent/IL176769A/en not_active IP Right Cessation
- 2006-07-11 US US11/456,708 patent/US7439257B2/en not_active Expired - Fee Related
- 2006-08-03 MA MA29230A patent/MA28343A1/fr unknown
- 2006-08-16 NO NO20063681A patent/NO20063681L/no not_active Application Discontinuation
2007
- 2007-10-08 CY CY20071101288T patent/CY1106918T1/el unknown
2008
- 2008-08-21 US US12/195,906 patent/US7674805B2/en not_active Expired - Fee Related
2010
- 2010-01-21 US US12/691,384 patent/US8026258B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL176769A (en)	2010-06-30
ZA200605698B (en)	2007-11-28
DE602005001930D1 (de)	2007-09-20
TWI402067B (zh)	2013-07-21
BRPI0506918A (pt)	2007-06-05
FR2865205A1 (fr)	2005-07-22
US20100120845A1 (en)	2010-05-13
WO2005077898A1 (fr)	2005-08-25
US7439257B2 (en)	2008-10-21
US20080312262A1 (en)	2008-12-18
DK1708994T3 (da)	2007-11-26
AR047384A1 (es)	2006-01-18
US20070021424A1 (en)	2007-01-25
CN1922138A (zh)	2007-02-28
CA2552565C (fr)	2013-12-31
KR20070000478A (ko)	2007-01-02
US8026258B2 (en)	2011-09-27
HK1101283A1 (zh)	2007-10-12
JP2007522111A (ja)	2007-08-09
EP1708994B1 (fr)	2007-08-08
CA2552565A1 (fr)	2005-08-25
RU2006129640A (ru)	2008-02-27
TW200536524A (en)	2005-11-16
DE602005001930T2 (de)	2008-04-30
CN100537534C (zh)	2009-09-09
AU2005212868A1 (en)	2005-08-25
JP4705590B2 (ja)	2011-06-22
HRP20070421T3 (hr)	2007-10-31
EP1708994A1 (fr)	2006-10-11
RU2392269C2 (ru)	2010-06-20
CY1106918T1 (el)	2012-09-26
US7674805B2 (en)	2010-03-09
ATE369336T1 (de)	2007-08-15
NZ548530A (en)	2010-02-26
IL176769A0 (en)	2006-10-31
PT1708994E (pt)	2007-10-02
ES2289701T3 (es)	2008-02-01
RS50518B (sr)	2010-05-07
AU2005212868B2 (en)	2011-04-21
MA28343A1 (fr)	2006-12-01
KR101171462B1 (ko)	2012-08-07
NO20063681L (no)	2006-09-18
FR2865205B1 (fr)	2006-02-24
PL1708994T3 (pl)	2008-01-31

Publication	Publication Date	Title
MEP26408A (en)	2010-06-10	Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
ES2147223T3 (es)	2000-09-01	Derivados de indol como agonistas de tipo 5-ht1.
DE69812070D1 (de)	2003-04-17	Immununterdrückende Effekte von 8 substituierten Xanthinderivaten
DE60015927D1 (en)	2004-12-23	Phenylharnstoff und phenylthioharnstoffderivate
BR0008759A (pt)	2002-08-06	Métodos para a produção de proteinas contendo resìduos de cisteina livre
ES2063094T3 (es)	1995-01-01	Derivados de oximeter, procedimiento para su obtencion y fungicidas que les contienen.
NO20021001L (no)	2002-04-11	Radiofarmasöytiske produkter og fremgangsmåter for fremstilling derav
HRP20090577T8 (en)	2009-12-31	Use of crth2 antagonist compounds in therapy
NL300098I1 (nl)	2002-11-01	Thiophene sulfonamides useful as carbonic anhydrase inhibitors.
TR200200234T2 (tr)	2002-06-21	Tirozin Protein kinaz SYK purin türevleri inhibitörleri
EP1061076A4 (en)	2001-05-02	CYCLIC N-ACYLAMINE DERIVATIVES
JP2007537275A5 (no)	2011-04-21
HRP20080024T3 (hr)	2008-02-29	Derivati alkilpiperazinskih i alkilhomopiperazinskih karboksilata, njihovo dobivanje i njihova upotreba kao inhibitori enzima faah
HRP20120820T1 (hr)	2012-11-30	Spoj uracila koji ima inhibicijsko djelovanje na humanu deoksiuridin trifosfatazu ili njegove soli
RU2009114859A (ru)	2010-10-27	Производные бензимидазола в качестве селективных ингибиторов кислотной помпы
RU2005111590A (ru)	2005-11-20	2,4-замещенные индолы и их использование в качестве модуляторов 5-гт6
ES508653A0 (es)	1982-11-01	"procedimiento para la preparacion de 3,1-benzoxazin-2-onas".
CO4980887A1 (es)	2000-11-27	Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
FR2803593B1 (fr)	2002-02-15	Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0015167A (pt)	2002-07-09	Naftopiranos possuindo um substiiuinte perfluoroalquil na posição 5, preparação e composições e matrizes contendo-os
NO995594D0 (no)	1999-11-15	Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
ATE116647T1 (de)	1995-01-15	Thiophenderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES480602A1 (es)	1980-04-01	Un procedimiento para la preparacion de nuevos derivados de indol.
ATE358675T1 (de)	2007-04-15	Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol
EP0729957A4 (en)	1996-12-27	PYRIDINE COMPOUND AND ITS USE AS A REMEDY